Global Asset Lead, Oncology Therapy Area, Research and Development

Orion Pharma•Boston, MA

1d•Hybrid

About The Position

Orion Pharma is seeking an experienced Global Asset Lead (GAL) to oversee the strategic vision and successful delivery of a priority oncology program. This role involves leading a high-performing Global Program Team (GPT) in a dynamic matrix environment, integrating Clinical, Regulatory, CMC, Medical Affairs, and Commercial functions. The mission is to maximize the medical and commercial value of the asset from early transition (Phase 1/2) through global registration, launch, and life cycle management. The position requires a blend of technical depth (scientific and clinical rigor) and business acumen (BD, portfolio strategy, and market dynamics).

Requirements

Ph.D. in Life Sciences, Pharm.D., or an equivalent doctoral-level degree (e.g., MD).
Minimum of 15 years in pharmaceutical or biotechnology R&D.
Minimum of 8 years specifically in Oncology Asset Leadership or a similar high-level matrix role.
Documented success in leading a program through a global regulatory submission (NDA/BLA/MAA) and subsequent commercial launch.
Proven ability to influence and lead large cross-functional teams without direct line-management authority in a Big Pharma environment.
Experience managing large-scale program budgets.
Sophisticated understanding of NPV/Asset Valuation models.
Ability to pivot between high-level strategic discussions and technical deep dives.
Exceptional executive presence; able to challenge senior leadership.
Unwavering commitment to clinical data integrity and delivering meaningful outcomes to cancer patients.

Nice To Haves

Experience in BD, portfolio strategy, and market dynamics.
Experience with RWE and HEOR.
Experience with IO combinations and ADC sequencing.
Experience with global geographic considerations (e.g., China/Japan development).
Experience managing Joint Steering Committees (JSC) for co-development assets with industry partners.
Experience with due diligence on potential in-licensing opportunities.
Experience building and maintaining high-level relationships with global Key Opinion Leaders (KOLs).
Experience participating in strategic partnering/investor discussions.
Experience continuously monitoring the oncology landscape to adjust asset strategy.

Responsibilities

Lead the creation and annual update of the Integrated Development Plan (IDP), ensuring alignment across clinical, regulatory, technical, and commercial workstreams.
Develop, refine, and execute the Target Product Profile (TPP) to achieve a competitive and differentiated label.
Partner with Medical Affairs and Clinical to drive an integrated evidence generation strategy (including RWE and HEOR) for global market access and reimbursement.
Lead the Global Program Team (GPT) as the central decision-maker, ensuring alignment on asset objectives.
Serve as the primary liaison between R&D (CMC/Clinical) and downstream functions (Commercial/Market Access) to ensure launch readiness.
Proactively manage cross-functional priorities, trade-offs, and resource constraints.
Act as the lead presenter for the asset at Senior Executive Governance meetings (e.g., Investment Committees, Portfolio Boards) to secure funding and alignment.
Establish clear "Go/No-Go" decision points and present data to governance for portfolio prioritization.
Lead formal risk assessments and develop contingency/back-up scenarios for potential challenges.
Strategize and execute the expansion of the asset into new indications, earlier lines of therapy, and novel combination regimens.
Ensure the IDP includes global geographic considerations and mandatory pediatric investigation plans.
Lead collaborations with academic cooperative groups and manage Joint Steering Committees for co-development assets.
Serve as the asset expert for due diligence on potential in-licensing opportunities.
Build and maintain relationships with global Key Opinion Leaders (KOLs) and participate in strategic partnering/investor discussions.
Continuously monitor the oncology landscape for competitive intelligence and adjust asset strategy accordingly.